1 / 12

Artificial Liver Support Systems

Artificial Liver Support Systems. John McLinden Biomedical Engineering. A Brief Introduction. Liver failure leads to a buildup of toxins in the bloodstream Artificial liver support systems attempt to remove these toxins to increase survival times

vaughne
Download Presentation

Artificial Liver Support Systems

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Artificial Liver Support Systems John McLinden Biomedical Engineering

  2. A Brief Introduction • Liver failure leads to a buildup of toxins in the bloodstream • Artificial liver support systems attempt to remove these toxins to increase survival times • Ultimately, liver can repair itself or a transplant is needed • Most early artificial liver support systems insufficient[1]

  3. MARS and PDF • Molecular Adsorption and Recycling System (MARS) was among the first artificial liver support systems to show true promise • Used human albumin as a substrate[1] • Plasma diafiltration (PDF) is a newer, experimental system • Also uses albumin, but exchanges blood plasma and was developed to allow the passage of adiponectin (APN)[2]

  4. MARS Overview • Blood is pumped through an impermeable hollow fiber dialyzer with albumin containing dialysate • The molecules captured are filtered through a charcoal and anion exchange columns • Dialysate also goes through a single-pass dialyzer[3] http://onlinelibrary.wiley.com.uri.idm.oclc.org/doi/10.1053/jhep.2002.36130/pdf

  5. PDF Overview • Uses an anticoagulant, dialysate, replacement fluid, and a human plasma/albumin mixture • Also uses a membrane that allows the passage of APN, which is believed to have anti-inflammatory properties[2] http://onlinelibrary.wiley.com.uri.idm.oclc.org/doi/10.1111/1744-9987.12344/pdf

  6. MARS Results • Some studies reported increases in 30-day survivability compared to standard medical procedure[4] • One reported that MARS patients experienced an 8.3% mortality rate versus patients receiving standard medical treatment, who experienced a 50% mortality rate[3]

  7. MARS Results Cont. • However, recent reviews of multiple MARS studies claim that the system does not have a significant effect on 30-day survivability • It is possible that the data were skewed because sepsis may have begun before the treatments were administered, which is a significant complication.[4]

  8. PDF Results • PDF saw a significant increase in median APN levels (11.64μg/mL before PDF to 14.52μg/mL after PDF) • For comparison, plasma exchange (PE) patients experienced a drop in median APN levels (11.53μg/mL before PE to 7.22μg/mL after)[2] http://onlinelibrary.wiley.com.uri.idm.oclc.org/doi/10.1111/1744-9987.12344/pdf

  9. PDF Results Cont. • However, increased pore size of the membrane could have allowed inflammatory cytokines through as well • These could mitigate the beneficial effects of APN[2]

  10. Conclusion • MARS has been tested for many years, with mixed results • Further testing is required to understand the conditions under which MARS would be most effective[4] • PDF was able to significantly increase APN levels, but requires more research to determine if it will ever become common practice[2]

  11. References • [1] Maiwall, R. et. al. Liver dialysis in acute-on-chronic liver failure: current and future perspectives. Hepatology International, 8(2): 505-13, 2014. • [2] Yamamoto, H. et. al. Plasma adiponectin levels in acute liver failure patients treated with plasma filtration with dialysis and plasma exchange. Therapeutic Apheresis and Dialysis, 19(4): 349-353, 2015. • [3] HassaneinT. et. al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology, 36 (4): 949-58 2002. • [4] Wauters, J. & Wilmer, A. Albumin dialysis: current practice and future options. Liver International, 31 (s3): 9-12 2011.

  12. Questions?

More Related